loading page

Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
  • +4
  • Shuang Yang,
  • Chengbin Zhou,
  • Lei Zhang,
  • Yueting Xiong,
  • Yongtao Zheng,
  • Liuguan Bian,
  • xiaohui liu
Shuang Yang
Author Profile
Chengbin Zhou
Shanghai Jiao Tong University
Author Profile
Lei Zhang
Fudan University
Author Profile
Yueting Xiong
Fudan University
Author Profile
Yongtao Zheng
Shanghai Jiao Tong University
Author Profile
Liuguan Bian
Shanghai Jiao Tong University
Author Profile
xiaohui liu

Corresponding Author:[email protected]

Author Profile

Abstract

Purpose: Brain tumors, whether primary or secondary, have limited information about proteomic changes despite advances in the understanding of the driver gene mutations and heterogeneity within tumor cells. The purpose of this study is to distinguish primary and secondary brain tumors based on proteomics. Experimental Design: We assembled the most common primary tumors as follows: gliomas from WHO grade II to IV with or without IDH1 mutations; and BrMs with a wide range, including lung cancer (L.C), breast cancer (B.C), ovarian cancer (O.C), and colorectal cancer (C.C). A total of 29 tissue samples were analyzed by label free quantitative mass spectrometry-based proteomics. Results: In total, 8,370 protein groups were identified, and approximately 4,000 quantified protein groups were adopted for further analysis. Proteomic analysis of metastatic tumors reveals conserved features across multiple cancers. While proteomic heterogeneities were found for discriminating low- and high-grade of gliomas, as well as IDH1 mutant and wild-type gliomas. And distinct pathway-level differences among these two types of brain malignancies were revealed. The characteristic pathways of BrMs focused on proliferation and immunomodulation after colonizing the brain, whereas invasion processes were notably activated in gliomas. Conclusions and Clinical Relevance: We elucidated an extensive proteomic landscape of BrMs and gliomas, providing information for the development of potential therapeutic and diagnostic strategies for type-specific brain tumors.
01 Feb 2023Submitted to Clinical Applications
06 Feb 2023Assigned to Editor
06 Feb 2023Submission Checks Completed
06 Feb 2023Review(s) Completed, Editorial Evaluation Pending
07 Feb 2023Reviewer(s) Assigned
31 Mar 2023Editorial Decision: Revise Major
12 Jul 20231st Revision Received
12 Jul 2023Review(s) Completed, Editorial Evaluation Pending
14 Jul 2023Reviewer(s) Assigned
30 Aug 2023Editorial Decision: Accept